| Akari Therapeutics Plc (AKTX) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | ||||||||||||||||||||||||||||||||||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | ||||||||||||||||||||||||||||||||||
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | 14,190.17x | 397.26x | 719.13x | 2,850.75x | 2,990.81x | 2,891.88x | 2,673.11x | - | - | ||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Price to Unlevered FCF | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | .41x | .50x | .50x | .57x | .56x | 3.45x | 1.73x | 2.28x | 1.05x | .87x | .26x | .30x | .48x | .67x | .40x | .35x | |||||||||||||||||||||||||||||||||
| Current Ratio | .44x | .19x | .19x | .16x | .15x | .29x | .58x | .44x | .95x | 3.79x | 3.30x | 2.09x | 3.04x | 4.70x | 2.85x | ||||||||||||||||||||||||||||||||||